Journal article
Prediction of amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological tests
A Bahar-Fuchs, V Villemagne, K Ong, G Chetélat, F Lamb, CB Reininger, M Woodward, CC Rowe
Journal of Alzheimer S Disease | Published : 2013
Abstract
Assessment of disease biomarkers, particularly the in vivo assessment of amyloid-β (Aβ) burden with positron emission tomography (PET), is gradually becoming central to the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease (AD). However, the incorporation of biomarker evidence to the diagnostic process is currently restricted mainly to research settings. The identification of memory measures that are associated with Aβ is of clinical relevance as this may enhance the confidence in making a diagnosis of MCI due to AD in clinical settings. Forty one persons with amnestic MCI underwent Aβ imaging with 18F-Florbetaben PET, magnetic resonance imaging, and a comprehensive neu..
View full abstractGrants
Funding Acknowledgements
Funding support for this study was provided by Bayer Schering Pharma as part of the Imaging A beta in MCI with <SUP>18</SUP>F-Florbetaben project. The funding source had no direct role in the design and conduct of the study, collection, analysis, interpretation of data, or preparation and review of this manuscript. The following people are acknowledged for their support: Greg Savage, Kerryn Pike, Narelle Langdon, Paul Yates, Svetlana Pejoska, Denise El-Sheikh, Rachel Mulligan, and Gareth Jones. We are also grateful to all the individuals who participated in the current study.